Invitrogen

Phospho-PRAS40 (Thr246) Polyclonal Antibody

Advanced Verification

This Antibody was verified by Cell treatment to ensure that the antibody binds to the antigen stated.

7 Published Figures

17 References

View all (32) PRAS40 antibodies

Datasheet

Protocols

Questions & Answers

Datasheet

Protocols

Questions & Answers

Phospho-PRAS40 (Thr246) Antibody in Immunohistochemistry (IHC)

FIGURE: 1 / 8

Phospho-PRAS40 (Thr246) Antibody (44-1100G) in IHC

Neuro-oncology 2012 - Published figure using Phospho-PRAS40 (Thr246) polyclonal antibody (Product # 44-1100G) in Immunohistochemistry

Phospho-PRAS40 (Thr246) Antibody in Western Blot (WB)

Product Image Gallery

Product Details

44-1100G

Applications

Tested Dilution

Publications

Western Blot (WB)

1:1,000

View 10 publications 10 publications

Immunohistochemistry (IHC)

Assay-dependent

View 4 publications 4 publications

Immunocytochemistry (ICC/IF)

View 1 publication 1 publication

Immunoprecipitation (IP)

View 1 publication 1 publication

Dot blot (DB)

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human, Mouse

Published species

Human, Mouse, Rat

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human PRAS40 that contains threonine 246.

View immunogen

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Purification

Antigen affinity chromatography

Storage buffer

Dulbecco's PBS, pH 7.3, with 1mg/mL BSA

Contains

0.05% sodium azide

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2533573

Product Specific Information

The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated PRAS40. The final product is generated by affinity chromatography using a PRAS40-derived peptide that is phosphorylated at threonine 246.

The antibody has been used in western blotting with NIH3T3 cells +/- PDGF, as positive control. Previous lots of this antibody have been used in immunocytochemistry and immunohistochemistry. Other applications may work but have not been tested.

Target Information

The Akt signaling pathway contributes to the regulation of apoptosis after a variety of cell death signals. AKT1S1, also known as PRAS40, is a proline-rich substrate of the kinase AKT1 and is thought to play a role in neuroprotection mediated by nerve growth factor (NGF) after transient focal cerebral ischemia. AKT1S1 is also a substrate and potential regulator of mammalian target of rapamycin (mTOR), a serine/threonine kinase that regulates cell growth and cell cycle, and a negative regulator of autophagy. Treatment with the insulin-like growth factor-1 (IGF1) can induce the phosphorylation of AKT1S1 via the PI3K/AKT signaling pathway in PC12 cells.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma.

Cancers

Sun K,Jin L,Karolová J,Vorwerk J,Hailfinger S,Opalka B,Zapukhlyak M,Lenz G,Khandanpour C

44-1100G was used in Western Blotting to provide a scientific rationale for the simultaneous inhibition of mTOR and MEK as a novel strategy for the treatment of MM.

Wed Apr 19 00:00:00 EDT 2023

EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC.

Cancer discovery

Krishnamoorthy GP,Davidson NR,Leach SD,Zhao Z,Lowe SW,Lee G,Landa I,Nagarajah J,Saqcena M,Singh K,Wendel HG,Dogan S,Tamarapu PP,Blenis J,Ghossein RA,Knauf JA,Rätsch G,Fagin JA

44-1100G was used in Western Blotting to describe the identification of the key signaling drivers of transformation by EIF1AX mutants, particularly EIF1AX-A113splice, alone and in the context of RAS, and the therapeutic dependencies they confer.

Fri Feb 01 00:00:00 EST 2019

Integrated Molecular Characterization of Uterine Carcinosarcoma.

Cancer cell

Cherniack AD,Shen H,Walter V,Stewart C,Murray BA,Bowlby R,Hu X,Ling S,Soslow RA,Broaddus RR,Zuna RE,Robertson G,Laird PW,Kucherlapati R,Mills GB,Weinstein JN,Zhang J,Akbani R,Levine DA

441100G was used in reverse phase protein array to characterize the molecular identity of uterine carcinosarcomas.

Mon Mar 13 00:00:00 EDT 2017

Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling.

Cell systems

Hill SM,Nesser NK,Johnson-Camacho K,Jeffress M,Johnson A,Boniface C,Spencer SE,Lu Y,Heiser LM,Lawrence Y,Pande NT,Korkola JE,Gray JW,Mills GB,Mukherjee S,Spellman PT

441100G was used in western blot to analyze the context specificity of signaling networks within a causal conceptual framework using reverse-phase protein array time-course assays and network analysis approaches

Wed Jan 25 00:00:00 EST 2017

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.

Oncotarget

Lynch JT,McEwen R,Crafter C,McDermott U,Garnett MJ,Barry ST,Davies BR

441100G was used in western blot to find tumor types sensitive to phosphoinositide 3-kinase pathway inhibitors

Tue Apr 19 00:00:00 EDT 2016

The Role of PDE3B Phosphorylation in the Inhibition of Lipolysis by Insulin.

Molecular and cellular biology

DiPilato LM,Ahmad F,Harms M,Seale P,Manganiello V,Birnbaum MJ

44-1100G was used in western blot to demonstrate that phosphorylation of PDE3B by Akt is not required for insulin to suppress adipocyte lipolysis.

Sat Aug 01 00:00:00 EDT 2015

Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.

Oncoscience

Webber PJ,Park C,Qui M,Ramalingam SS,Khuri FR,Fu H,Du Y

44-1100G was used in western blot to assess the impact of heat shock protein 90 inhibition in combination with focal adhesion kinase inhibitor on the growth of non-small cell lung cancer cells.

Tue Oct 27 00:00:00 EDT 2015

Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.

Molecular cancer therapeutics

Yu P,Laird AD,Du X,Wu J,Won KA,Yamaguchi K,Hsu PP,Qian F,Jaeger CT,Zhang W,Buhr CA,Shen P,Abulafia W,Chen J,Young J,Plonowski A,Yakes FM,Chu F,Lee M,Bentzien F,Lam ST,Dale S,Matthews DJ,Lamb P,Foster P

44-1100G was used in western blot to study the anti-tumor effects of a pan class I PI3 kinase/mTOR inhibitor in cells with a genetically diverse range of PI3 kinase pathway modifications.

Thu May 01 00:00:00 EDT 2014

PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.

Neuro-oncology

Mueller S,Phillips J,Onar-Thomas A,Romero E,Zheng S,Wiencke JK,McBride SM,Cowdrey C,Prados MD,Weiss WA,Berger MS,Gupta N,Haas-Kogan DA

Published figure using Phospho-PRAS40 (Thr246) polyclonal antibody (Product # 44-1100G) in Immunohistochemistry

Sat Sep 01 00:00:00 EDT 2012

Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1.

Cellular signalling

Nascimento EB,Snel M,Guigas B,van der Zon GC,Kriek J,Maassen JA,Jazet IM,Diamant M,Ouwens DM

Tue Jun 01 00:00:00 EDT 2010

Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1.

Cellular signalling

Nascimento EB,Snel M,Guigas B,van der Zon GC,Kriek J,Maassen JA,Jazet IM,Diamant M,Ouwens DM

Tue Jun 01 00:00:00 EDT 2010

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.

Journal of neuro-oncology

McBride SM,Perez DA,Polley MY,Vandenberg SR,Smith JS,Zheng S,Lamborn KR,Wiencke JK,Chang SM,Prados MD,Berger MS,Stokoe D,Haas-Kogan DA

44-1100G was used in immunohistochemistry to study the impact of the Akt-mTOR pathway in low-grade gliomas

Mon Mar 01 00:00:00 EST 2010

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.

Cancer cell

Guertin DA,Stevens DM,Saitoh M,Kinkel S,Crosby K,Sheen JH,Mullholland DJ,Magnuson MA,Wu H,Sabatini DM

Tue Feb 03 00:00:00 EST 2009

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.

Cancer cell

Guertin DA,Stevens DM,Saitoh M,Kinkel S,Crosby K,Sheen JH,Mullholland DJ,Magnuson MA,Wu H,Sabatini DM

Tue Feb 03 00:00:00 EST 2009

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.

Cancer cell

Guertin DA,Stevens DM,Saitoh M,Kinkel S,Crosby K,Sheen JH,Mullholland DJ,Magnuson MA,Wu H,Sabatini DM

Tue Feb 03 00:00:00 EST 2009

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.

Cancer cell

Guertin DA,Stevens DM,Saitoh M,Kinkel S,Crosby K,Sheen JH,Mullholland DJ,Magnuson MA,Wu H,Sabatini DM

Tue Feb 03 00:00:00 EST 2009

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

PLoS medicine

Cloughesy TF,Yoshimoto K,Nghiemphu P,Brown K,Dang J,Zhu S,Hsueh T,Chen Y,Wang W,Youngkin D,Liau L,Martin N,Becker D,Bergsneider M,Lai A,Green R,Oglesby T,Koleto M,Trent J,Horvath S,Mischel PS,Mellinghoff IK,Sawyers CL

Tue Jan 22 00:00:00 EST 2008

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

PLoS medicine

Tue Jan 22 00:00:00 EST 2008

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.

Nature cell biology

Vander Haar E,Lee SI,Bandhakavi S,Griffin TJ,Kim DH

Thu Mar 01 00:00:00 EST 2007

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.

Nature cell biology

Vander Haar E,Lee SI,Bandhakavi S,Griffin TJ,Kim DH

Thu Mar 01 00:00:00 EST 2007

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.

Nature cell biology

Vander Haar E,Lee SI,Bandhakavi S,Griffin TJ,Kim DH

Thu Mar 01 00:00:00 EST 2007

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.

Nature cell biology

Vander Haar E,Lee SI,Bandhakavi S,Griffin TJ,Kim DH

Thu Mar 01 00:00:00 EST 2007

Target validation in drug discovery.

Methods in molecular biology (Clifton, N.J.)

Blake RA

Tue Nov 21 00:00:00 EST 2006

Bioinformatics

Protein Aliases: 40 kDa proline-rich AKT substrate; AKT1 substrate 1 (proline rich); AKT1 substrate 1 (proline-rich); AKT1S1; OTTHUMP00000196756; OTTHUMP00000196760; Proline-rich AKT substrate; Proline-rich AKT1 substrate 1

View more View less

Gene Aliases: 1110012J22Rik; AI227026; AKT1S1; Lobe; Lobel; Pras; PRAS40

View more View less

UniProt ID: (Human) Q96B36, (Mouse) Q9D1F4

View more View less

Entrez Gene ID: (Human) 84335, (Mouse) 67605

View more View less

Function(s)

protein binding

Process(es)

negative regulation of protein kinase activity negative regulation of TOR signaling regulation of neuron apoptotic process negative regulation of cell size neurotrophin TRK receptor signaling pathway regulation of cellular response to heat Notch signaling pathway

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

Phospho-PRAS40 (Thr246) Polyclonal Antibody

Phospho-PRAS40 (Thr246) Antibody (44-1100G) in IHC

Product Details

44-1100G

Western Blot (WB)

Immunohistochemistry (IHC)

Immunocytochemistry (ICC/IF)

Immunoprecipitation (IP)

Dot blot (DB)

Species Reactivity

Published species

Host/Isotype

Class

Type

Immunogen

Conjugate

Form

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Product Specific Information

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!